Publication Name	World Journal of Hepatology
Manuscript ID	12934
Country	United States

Received	2014-07-29 08:22
Peer-Review Started	2014-07-29 19:18
To Make the First Decision	2014-08-28 14:57
Return for Revision	2014-09-01 09:58
Revised	2014-09-13 01:29
Second Decision	2014-10-10 18:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-10-10 18:26
Articles in Press	2014-10-10 18:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-20 09:15
Publish the Manuscript Online	2014-11-20 19:46

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Mammalian target of rapamycin inhibition in hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	René E Ashworth and Jennifer Wu
Funding Agency and Grant Number
Corresponding Author	Jennifer Wu, MD, Assistant Professor of Medicine, NYU School of Medicine, Subdivision of GI Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, Division of Hematology and Oncology, 550 First Avenue, BCD 556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Key Words	Mammalian target of rapamycin; hepatocellular carcinoma; Mammalian target of rapamycin complex 1; Mammalian target of rapamycin complex 2; PI3K/AKT/mTOR signaling pathway; Sorafenib; Everolimus; Sirolimus; Liver transplantation; CC-223
Core Tip	Advanced hepatocellular carcinoma (HCC) has a poor prognosis with limited therapeutic options. The mammalian target of rapamycin (mTOR) pathway (regulated by mTORC1 and mTORC2) is implicated in HCC pathogenesis. This review examines pre-clinical and clinical data demonstrating that mTORC1 inhibition effectively prevents HCC recurrence post-liver transplantation, and also has a modest anti-tumor effect in advanced HCC. The rationale and preclinical data for utilizing dual mTOR (mTORC1 and mTORC2) inhibition in HCC is also reviewed; a current phase?Ⅰ?clinical trial to investigate the efficacy of dual mTOR inhibitors is briefly discussed. mTOR pathway inhibition has therapeutic potential in the treatment of advanced HCC.
Publish Date	2014-11-20 19:46
Citation	Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 2014; 6(11): 776-782
URL	http://www.wjgnet.com/1948-5182/full/v6/i11/776.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i11.776

Full Article (PDF)	WJH-6-776.pdf
Full Article (Word)	WJH-6-776.doc
Manuscript File	12934-Review.doc
Answering Reviewers	12934-Answering reviewers.pdf
Copyright License Agreement	12934-Copyright assignment.pdf
Peer-review Report	12934-Peer review(s).pdf
Scientific Misconduct Check	12934-CrossCheck.jpg
Scientific Editor Work List	12934-Scientific editor work list.pdf